---
title: "Protara Therapeutics CMO Nicacio resigns effective June 26, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291190167.md"
description: "Protara Therapeutics announced that Chief Medical Officer Leonardo Viana Nicacio resigned, effective June 26, 2026. His duties will be assumed by Lead Medical Director Carla Beckham, under the oversight of Chief Research & Development Officer Jacqueline Zummo."
datetime: "2026-06-29T21:03:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291190167.md)
  - [en](https://longbridge.com/en/news/291190167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291190167.md)
---

# Protara Therapeutics CMO Nicacio resigns effective June 26, 2026

-   Protara Therapeutics Chief Medical Officer Leonardo Viana Nicacio resigned, effective June 26, 2026. \* CMO duties shift to Lead Medical Director, Head of Clinical Development Carla Beckham under oversight of Chief Research & Development Officer Jacqueline Zummo. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073184), on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TARA.US](https://longbridge.com/en/quote/TARA.US.md)

## Related News & Research

- [Protara Therapeutics Q2 net loss widens on higher expenses](https://longbridge.com/en/news/295534784.md)
- [Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26](https://longbridge.com/en/news/295589045.md)
- [Aardvark Therapeutics held annual shareholder meeting](https://longbridge.com/en/news/296141463.md)
- [Damora Therapeutics director Andrew Cheng files initial beneficial ownership statement](https://longbridge.com/en/news/295846150.md)
- [Investors House to release H1 2026 results](https://longbridge.com/en/news/295920631.md)